UC BRAID Center for Accelerated Innovation

UC BRAID 加速创新中心

• 批准号: 8916929
• 负责人: MICHAEL J PALAZZOLO
• 金额: $ 97.75万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8916929
• 关键词: Acceleration; Accounting; Address; Adopted; Affect; American; Asthma; Atrial Fibrillation; Award; Biological Markers; Biomedical Engineering; Biomedical Research; Biopolymers; Blood Pressure; Businesses; California; Capital; Cardiac; Cardiac ablation; Cardiovascular Diseases; Cardiovascular Physiology; Cardiovascular system; Cause of Death; Cells; Cerebrovascular Disorders; Clinical; Clinical Research; Clinical Sciences; Clinical and Translational Science Awards; Collaborations; Communities; Congestive Heart Failure; Creativeness; Development; Devices; Diagnostic; Diagnostic tests; Disclosure; Ecosystem; Engineering; Ensure; Faculty; Funding; Goals; Grant; Hamman-Rich syndrome; Health; Health Sciences; Heart Diseases; Hematological Disease; Hydrogels; Implant; Incubated; Industrial Product; Industry; Intellectual Property; Investments; Joints; Knowledge; Laboratories; Legal; Legal patent; Licensing; Link; Los Angeles; Lung diseases; Mechanics; Medical; Medical Device; Mentors; Mentorship; Methods; Microscopy; Mission; Modeling; National Heart, Lung, and Blood Institute; Nonprofit Organizations; Organizational Innovation; Outcome; Pathology; Patient Care; Patients; Pharmaceutical Preparations; Positioning Attribute; Primates; Process; Productivity; Program Development; Pulmonary veins; Research; Research Infrastructure; Research Institute; Research Personnel; Resources; Retrieval; San Francisco; Staging; Structure; System; Technology; Technology Transfer; Testing; Therapeutic; Tissue Microarray; Tissues; Training and Education; Transfusion; Translating; Translational Research; Translations; United States Food and Drug Administration; United States National Institutes of Health; Universities; Ventricular; Work; base; blood product; commercialization; design; experience; fighting; hemodynamics; improved; innovation; medical schools; meetings; multidisciplinary; product development; programs; reconstruction; skills; small molecule; success; technology development; tissue repair; volunteer

The University of California Center for Accelerated Innovation proposes to create new mechanisms and to leverage its diverse strengths in diagnostics, therapeutics, and devices to support translation of promising early-stage inventions for patient benefit. The Center is a consortium of the five UC medical campuses: UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco. Each campus has a thriving research enterprise, nationally ranked medical school, and translational research institute funded by Clinical and Translational Science Awards (CTSA). Together, our five campuses account for nearly 7% of NHLBI's grant funding. The Center taps into the vigor and creativity of California's legendary biomedical and engineering ecosystem and integrates the many successful business, engineering and health sciences programs at our campuses. Our program will partner with well-established biomedical companies, venture capital firms, industry organizations and nonprofits focused on medical innovation. The Center is supported by UC Biomedical Research Acceleration, Integration, and Development (UC BRAID), a joint effort of the five UC biomedical campuses designed to catalyze and accelerate biomedical, clinical, and translational research across the UC system. Together we will: 1) Engage University of California heart, lung and blood disease innovators in entrepreneurism through a comprehensive education, training and mentorship program. 2) Solicit and select technologies with high commercial potential that align with NHLBI's mission and address unmet medical needs or significant scientific opportunity. 3) Incubate our most promising technologies in accordance with industry requirements to facilitate their translation to commercial products that improve patient care and enhance health. 4) Create a high-performing, sustainable infrastructure that will serve as a model to academic research centers. These programs will create an integrated, sustainable infrastructure to accelerate the translation of our NHLBI-funded discoveries to the marketplace in order to promote health and improve patient care.

加州大学加速创新中心建议建立新的机制， 利用其在诊断、治疗和设备方面的多种优势， 早期的发明来造福病人该中心是五个UC医学校区的联盟：UC 戴维斯，加州大学欧文分校，加州大学洛杉矶分校，加州大学圣地亚哥分校和加州大学旧金山弗朗西斯科分校。每个校园都有一个蓬勃发展的 研究企业、全国排名靠前的医学院和临床资助的转化研究机构 翻译科学奖（CTSA）我们的五个校区加起来占NHLBI的近7% 赠款资金。 该中心利用了加州传奇生物医学和工程生态系统的活力和创造力 并整合了许多成功的商业，工程和健康科学计划在我们的校园。 我们的计划将与成熟的生物医学公司，风险投资公司，工业合作伙伴 专注于医疗创新的组织和非营利组织。该中心由UC Biomedical提供支持 研究加速，集成和开发（UC BRAID），五个UC生物医学的共同努力 校园旨在催化和加速整个UC的生物医学，临床和转化研究 系统我们将共同：1）让加州大学的心脏，肺和血液疾病创新者参与 通过全面的教育、培训和指导计划实现自我管理。2)征求和选择 具有高商业潜力的技术，符合NHLBI的使命，并解决未满足的医疗需求 需要或重大的科学机会。3)孵化我们最有前途的技术， 行业要求，以促进其转化为改善患者护理的商业产品， 增强健康。4)创建高性能、可持续的基础设施，作为 学术研究中心。 这些计划将建立一个综合的、可持续的基础设施，以加快我们的 NHLBI资助的发现推向市场，以促进健康和改善病人护理。